Clinical research of mycophenolate mofetil and cyclophosphamide in the treatment of Children Henoch-Schonlein pur-pura nephritis accompanied by nephrotic syndrome

苗静,周俊霖,彭晓杰,郑卫民,傅睿,黄玉辉
DOI: https://doi.org/10.3969/j.issn.1006-2238.2015.11.002
2015-01-01
Abstract:Objective To compare the therapeutic effects and side effects of mycophenolate mofetil (MMF) and cyclophos-phamide (CTX) in the treatment of Children Henoch-Schonlein purpura nephritis (HSPN) accompanied by nephrotic syndrome. Methods Thirty-one children who suffered from HSPN with nephrotic-range proteinuria and hematuria or with only nephrotic-range proteinuria were given intravenous administration of pulse methylprednisolone firstly ,who did not respond to the treatment were enrolled. These patients were divided into two groups. Nineteen patients were treated with oral intake of MMF (MMF group) 20-25mg·kg-1·d-1 for 6months,then gradually withdrawn at the 12th month. Other twelve patients were treated with intravenous pulse administration of cyclophosphamide (CTX group, 10 mg·kg-1·d-1,2 days) once every two weeks,6-8 course of treatments totally. Clinical assessment,24-hour urinary protein,creatinine clearance (CCr),liver function and side effects were performed at the 3rd,6th and 12th month. Results The complete remission rates in the 6th,12th month after MMF and CTX therapy were 42. 1%and 41.7%,84.2%and 75.0%(P>0.05),respectively. The total remission rates were 94.7%and 91.7%(P>0.05);There was no significant difference in the efficiency rate between MMF and CTX. The side effects of MMF were much weak.The side effects of CTX included the decreased white blood cells and vomitting. Conclusion There is no significant difference in the efficiency rate between MMF and CTX for treating Children Henoch-Schonlein purpura nephritis (HSPN) accompanied by nephrotic syndrome. Side effects of MMF were obviously fewer than CTX.
What problem does this paper attempt to address?